Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says
Executive Summary
Outcomes measures should go beyond self-reported pain scores to include effects on function and quality of life, advisory committee members said during review of Teva's long-acting opioid Vantrela.
You may also be interested in...
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
As Egalet's Arymo ER heads to panel, agency tries to head off discussion about whether it should be approving new opioid products and whether longer clinical efficacy trials should be demanded.
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.